Alveolar macrophages autoregulate IL-1 and IL-6 production by endogenous nitric oxide

被引:41
作者
Persoons, JHA
Schornagel, K
Tilders, FFH
deVente, J
Berkenbosch, F
Kraal, G
机构
[1] FREE UNIV AMSTERDAM,FAC MED,DEPT PHARMACOL,NEUROSCI RES INST,1081 BT AMSTERDAM,NETHERLANDS
[2] UNIV LIMBURG,DEPT PSYCHIAT & NEUROPSYCHOL,6200 MD MAASTRICHT,NETHERLANDS
关键词
D O I
10.1165/ajrcmb.14.3.8845178
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of nitric oxide on the lipopolysaccharide (LPS)-induced cytokine production by alveolar macrophages was studied. When alveolar macrophages were cultured, substantial amounts of interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and nitric oxide are produced upon stimulation with LPS. Inhibition of the nitric oxide production by the L-arginine analogue N-G-monomethyl-L-arginine (NMMA), resulted in an increase of IL-1 beta and IL-6, whereas the TNF-alpha concentrations remained unchanged, suggesting specific inhibitory effects of nitric oxide on the LPS-stimulated cytokine production by alveolar macrophages. The observed cytokine-modulating properties of nitric oxide did not result from cytotoxic actions of the oxidation of L-arginine on macrophages, since nitric oxide synthesis did not affect the viability of the alveolar macrophages. Conversely the nitric oxide donor S-nitroso-N-acetyl-D, L-penicillamine (SNAP) induced dose-dependent inhibition of IL-1 production in LPS-stimulated alveolar macrophages in which endogenous nitric oxide production was blocked. The results indicate that nitric oxide can affect the LPS-induced IL-1 beta and IL-6 secretion by alveolar macrophages in an autoregulatory way and are discussed in view of the important physiologic consequences this autoregulation by nitric oxide may have.
引用
收藏
页码:272 / 278
页数:7
相关论文
共 54 条
[51]   A STUDY OF SOME VARIABLES IN A TETRAZOLIUM DYE (MTT) BASED ASSAY FOR CELL-GROWTH AND CHEMOSENSITIVITY [J].
TWENTYMAN, PR ;
LUSCOMBE, M .
BRITISH JOURNAL OF CANCER, 1987, 56 (03) :279-285
[52]  
UNANUE ER, 1989, FUNDAMENTAL IMMUNOLO, P95
[53]  
WALDMAN SA, 1987, PHARMACOL REV, V39, P163
[54]  
ZUCKERMAN SH, 1991, IMMUNOLOGY, V73, P460